|
MCID: CRD216
MIFTS: 36
|
Ceroid Lipofuscinosis, Neuronal, 9
Categories:
Rare diseases, Neuronal diseases, Metabolic diseases, Genetic diseases
|
|
|
|
MalaCards integrated aliases for Ceroid Lipofuscinosis, Neuronal, 9:
Characteristics:Orphanet epidemiological data:59
cln9 disease
Inheritance: Autosomal recessive; Age of onset: Childhood; OMIM:57
Inheritance:
autosomal recessive
Miscellaneous:
early death one family has been reported (last curated march 2016) onset at 4 years of age similar phenotype to juvenile neuronal ceroid lipofuscinosis 3 (cln3, ) HPO:32
ceroid lipofuscinosis, neuronal, 9:
Mortality/Aging death in childhood Inheritance autosomal recessive inheritance Classifications:
MalaCards categories:
Global: Rare diseases Metabolic diseases Genetic diseases Anatomical: Neuronal diseases
ICD10:
33
34
|
|
NIH Rare Diseases
:
53
Neuronal ceroid lipofuscinosis 9 (CLN9-NCL) is a rare condition that affects the nervous system. Signs and symptoms of the condition generally develop in early childhood (average age 4 years) and may include loss of muscle coordination (ataxia), seizures that do not respond to medications, muscle twitches (myoclonus), visual impairment, and developmental regression (the loss of previously acquired skills). The underlying genetic cause of CLN9-NCLÂ is unknown but it appears to be inherited in an autosomal recessive manner. Treatment options are limited to therapies that can help relieve some of the symptoms.
MalaCards based summary : Ceroid Lipofuscinosis, Neuronal, 9, also known as neuronal ceroid lipofuscinosis 9, is related to neuronal ceroid lipofuscinosis and cerebral atrophy, and has symptoms including ataxia, muscle rigidity and seizures. An important gene associated with Ceroid Lipofuscinosis, Neuronal, 9 is CLN9 (Ceroid-Lipofuscinosis, Neuronal 9), and among its related pathways/superpathways is Lysosome. The drugs Belinostat and Histone Deacetylase Inhibitors have been mentioned in the context of this disorder. Related phenotypes are intellectual disability and seizures Disease Ontology : 12 A neuronal ceroid lipofuscinosis that is characterized by juvenile-onset of progressive vision loss, progressive ataxia and seziures. OMIM : 57 The neuronal ceroid lipofuscinoses (NCL; CLN) are a clinically and genetically heterogeneous group of neurodegenerative disorders characterized by the intracellular accumulation of autofluorescent lipopigment storage material in different patterns ultrastructurally. The clinical course includes progressive dementia, seizures, and progressive visual failure (Mole et al., 2005). For a discussion of genetic heterogeneity of neuronal ceroid lipofuscinosis, see CLN1 (256730). (609055) |
Symptoms via clinical synopsis from OMIM:57Clinical features from OMIM:609055Human phenotypes related to Ceroid Lipofuscinosis, Neuronal, 9:32 (show all 17)
UMLS symptoms related to Ceroid Lipofuscinosis, Neuronal, 9:ataxia, muscle rigidity, seizures, scanning speech MGI Mouse Phenotypes related to Ceroid Lipofuscinosis, Neuronal, 9:46
|
Drugs for Ceroid Lipofuscinosis, Neuronal, 9 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
Interventional clinical trials:
|
Genes related to Ceroid Lipofuscinosis, Neuronal, 9 (0 elite genes):
- Elite gene
- Cancer Census gene in COSMIC
|
|
|
|
Search
GEO
for disease gene expression data for Ceroid Lipofuscinosis, Neuronal, 9.
|
Cellular components related to Ceroid Lipofuscinosis, Neuronal, 9 according to GeneCards Suite gene sharing:
Biological processes related to Ceroid Lipofuscinosis, Neuronal, 9 according to GeneCards Suite gene sharing:
|
|